The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated pooled analyses of first-line anti-PD1/PD-L1 inhibitors plus chemotherapy in advanced esophageal squamous cell carcinoma.
 
Maysa Vilbert
No Relationships to Disclose
 
Jonathan N Priantti
No Relationships to Disclose
 
Thiago Madeira
No Relationships to Disclose
 
Francisco Cezar A Moraes
No Relationships to Disclose
 
Alireza Tojjari
No Relationships to Disclose
 
Ibrahim Halil Sahin
Consulting or Advisory Role - GlaxoSmithKline
 
Ludimila Cavalcante
Employment - Actuate Therapeutics
Stock and Other Ownership Interests - Actuate Therapeutics
Consulting or Advisory Role - Pliant
 
Anwaar Saeed
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Exelixis; Five Prime Therapeutics; Pfizer
Research Funding - Actuate Therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo/UCB Japan (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); innovent biologics (Inst); KAHR Medical (Inst); Merck Sharp & Dohme (Inst); Seagen (Inst)